Challenges in the combination of radiotherapy and immunotherapy for breast cancer

Introduction: Immunotherapy (IT) is showing promise in the treatment of breast cancer, but IT alone only benefits a minority of patients. Radiotherapy (RT) is usually included in the standard of care for breast cancer patients and is traditionally considered as a local form of treatment. The emerging knowledge of RT-induced systemic immune response, and the observation that the rare abscopal effect of RT on distant cancer metastases can be augmented by IT, have increased the enthusiasm for combinatorial immunoradiotherapy (IRT) for breast cancer patients. However, IRT largely follows the traditional sole RT and IT protocols and does not consider patient specificity, although patients' responses to treatment remain heterogeneous.Areas covered: This review discusses the rationale of IRT for breast cancer, the current knowledge, challenges, and future directions.Expert opinion: The synergy between RT and the immune system has been observed but not well understood at the basic level. The optimal dosages, timing, target, and impact of biomarkers are largely unknown. There is an urgent need to design efficacious pre-clinical and clinical trials to optimize IRT for cancer patients, maximize the synergy of radiation and immune response, and explore the abscopal effect in depth, taking into account patients' personal features.

Automated summary

Immunotherapy combined with radiotherapy shows promise in breast cancer treatment, but more research is needed to optimize the synergy between the two treatments and personalize IRT for individual patients. The abscopal effect of radiotherapy on distant cancer metastases and the potential impact of biomarkers need further exploration. Designing effective pre-clinical and clinical trials is urgently needed to improve IRT for breast cancer patients.